Chimerix, Inc. announced that M. Michelle Berrey, M.D., M.P.H., has resigned from her role as the company's President and Chief Executive Officer. W. Garrett Nichols, Timothy W. Trost and Michael A. Alrutz have been appointed as members of a newly created position, the Office of the Chief Executive Officer, on an interim basis until a replacement is found. In addition to their new roles within the Office of the Chief Executive Officer, Dr. Nichols will continue to serve as the company's Chief Medical Officer; Mr. Trost will continue to serve as the company's Senior Vice President, Chief Financial Officer and Corporate Secretary; and Mr. Alrutz will continue to serve as Chimerix's Senior Vice President, General Counsel.
Chimerix, Inc. is a biotechnology company. The Company is focused on developing medicines that address unmet medical needs. The Company's product Imipridones is a cancer therapy that provides ONC201, which is in clinical-stage development for H3 K27M-mutant glioma as its lead indication. In addition, imipridone ONC206 is in dose-escalating clinical trials. Imipridones target specific G protein-coupled receptors (GPCRs) and mitochondrial caseinolytic protease P (ClpP), resulting in cancer cell death. The Company's product Imipridone chemical scaffold provides an opportunity to target GPCRs and ClpP with tunable specificity and modality, which enables therapeutic use for cancer and other diseases. Its ONC206 is an imipridone, Dopamine Receptor D2 (DRD2) antagonist and ClpP agonist. Its ONC212 is an imipridone, an investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP. Its CMX521 is a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2.